Michael Bagwell, DO
Family Medicine · Senatobia, MSNPI 1558306019
Payments from drug & device makers
Across 735 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AbbVie$940
- Boehringer Ingelheim$840
- Johnson & Johnson$799
- plus $6K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 81 | $1,606 |
| Novo Nordisk | 81 | $1,461 |
| Lilly USA, LLC | 91 | $1,278 |
| AbbVie(2 entities) | 59 | $940 |
| Boehringer Ingelheim | 52 | $840 |
| Johnson & Johnson | 49 | $799 |
| GSK | 43 | $715 |
| Amarin Pharma, Inc. | 38 | $644 |
| Amgen | 39 | $615 |
| Bayer | 24 | $603 |
| Pfizer | 36 | $529 |
| Dexcom, Inc. | 11 | $314 |
| Esperion Therapeutics, Inc. | 13 | $313 |
| Abbott | 16 | $304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $219 |
| Sumitomo Pharma America, Inc. | 9 | $167 |
| Mylan Specialty L.p. | 6 | $165 |
| Merck | 7 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $136 |
| Sanofi-aventis U.S. LLC | 8 | $126 |
| Teva Pharmaceuticals USA, Inc. | 8 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $122 |
| Novartis | 6 | $105 |
| Viatris Specialty LLC | 3 | $68 |
| Eisai Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Impel Pharmaceuticals Inc. | 3 | $48 |
| Exact Sciences | 3 | $41 |
| Genentech USA, Inc. | 3 | $41 |
| Astellas Pharma US Inc | 2 | $36 |
| Boston Scientific | 1 | $36 |
| IBSA Pharma Inc. | 2 | $33 |
| Heartflow, Inc. | 1 | $19 |
| Vertex | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$12,738 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Senatobia
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.